Domains and Functions of Spike Protein in Sars-Cov-2 in the Context of Vaccine Design
| dc.contributor.author | Xia, Xuhua | |
| dc.date.accessioned | 2021-02-17T16:10:02Z | |
| dc.date.available | 2021-02-17T16:10:02Z | |
| dc.date.issued | 2021 | |
| dc.description.abstract | The spike protein in SARS-CoV-2 (SARS-2-S) interacts with the human ACE2 receptor to gain entry into a cell to initiate infection. Both Pfizer/BioNTech's BNT162b2 and Moderna's mRNA-1273 vaccine candidates are based on stabilized mRNA encoding prefusion SARS-2-S that can be produced after the mRNA is delivered into the human cell and translated. SARS-2-S is cleaved into S1 and S2 subunits, with S1 serving the function of receptor-binding and S2 serving the function of membrane fusion. Here, I dissect in detail the various domains of SARS-2-S and their functions discovered through a variety of different experimental and theoretical approaches to build a foundation for a comprehensive mechanistic understanding of how SARS-2-S works to achieve its function of mediating cell entry and subsequent cell-to-cell transmission. The integration of structure and function of SARS-2-S in this review should enhance our understanding of the dynamic processes involving receptor binding, multiple cleavage events, membrane fusion, viral entry, as well as the emergence of new viral variants. I highlighted the relevance of structural domains and dynamics to vaccine development, and discussed reasons for the spike protein to be frequently featured in the conspiracy theory claiming that SARS-CoV-2 is artificially created. | en_US |
| dc.description.sponsorship | NSERC | en_US |
| dc.identifier.citation | Xia, X. 2021. Domains and Functions of Spike Protein in SARS-Cov-2 in the Context of Vaccine Design. Viruses 13(1), 109 | en_US |
| dc.identifier.doi | 10.3390/v13010109 | en_US |
| dc.identifier.issn | 1999-4915 | en_US |
| dc.identifier.uri | https://pubmed.ncbi.nlm.nih.gov/33466921/ | en_US |
| dc.identifier.uri | http://hdl.handle.net/10393/41782 | |
| dc.identifier.uri | https://doi.org/10.20381/ruor-26004 | |
| dc.language.iso | en | en_US |
| dc.subject | COVID-19 | en_US |
| dc.subject | S-2P | en_US |
| dc.subject | SARS-CoV-2 | en_US |
| dc.subject | cleavage | en_US |
| dc.subject | hydrophobicity | en_US |
| dc.subject | isoelectric point | en_US |
| dc.subject | protein structure | en_US |
| dc.subject | spike protein | en_US |
| dc.subject | vaccine | en_US |
| dc.subject | COVID-19 | en_US |
| dc.subject | COVID-19 Vaccines | en_US |
| dc.subject | Humans | en_US |
| dc.subject | Membrane Fusion | en_US |
| dc.subject | Mutation | en_US |
| dc.subject | Protein Binding | en_US |
| dc.subject | Protein Domains | en_US |
| dc.subject | Protein Stability | en_US |
| dc.subject | Receptors, Virus | en_US |
| dc.subject | SARS-CoV-2 | en_US |
| dc.subject | Spike Glycoprotein, Coronavirus | en_US |
| dc.subject | Virus Internalization | en_US |
| dc.title | Domains and Functions of Spike Protein in Sars-Cov-2 in the Context of Vaccine Design | en_US |
| dc.type | Article | en_US |
